

Special Issue

Antibiotics in the Critically Ill Patient

Message from the Guest Editors

Infectious issues have always been a major concern in the management of critically ill patients. Clinical features and the derangement of several physiological and pharmacological traits require a distinctive and careful approach. As a result, intensivist physicians developed a high level of interest in the area of infections and an aptitude for multidisciplinary dialogue with microbiologists, infectious disease specialists, pharmacologists, and all professionals involved in these topics. The introduction in clinical practice of molecular biology techniques and the release of a dozen new antibiotic molecules are leading to rapid generational change in the diagnostic/therapeutic paradigm. Hence, we believe that a Special Issue of *Antibiotics* focusing on critically ill patients is of great significance. The aim is to report research, experiences, works, ideas, and strategies on these topics. We are looking for papers about innovative diagnostic techniques, recently introduced molecules, pharmacodynamic/pharmacokinetic features, epidemiological data, risk stratification strategy, and multidrug-resistant bacteria management.

Guest Editors

Dr. Emanuele Russo

Dr. Vanni Agnoletti

Prof. Dr. Fausto Catena

Dr. Bruno Viaggi

Deadline for manuscript submissions

closed (28 February 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/162975

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)